India's Richest People 2026 edition · 1 director · Source: Hurun India
- #102 Kiran Mazumdar-Shaw ₹32,900 Cr
Revenue · FY 2025
₹982.5 Cr
▲ 11% YoY
Net profit · FY 2025
₹82.3 Cr
Net margin 8.4%
EBITDA · FY 2025
₹137.2 Cr
EBITDA margin 14%
Authorised capital
₹1,040.15 Cr
Registered with MCA
Paid-up capital
₹887.1 Cr
Issued & subscribed
Satisfied charges
₹133 Cr
No open charges
Company age
12 yrs
Est. 2014
Employees · EPFO
526
Provident fund records
About Biocon Pharma Limited
Data last updated:
Biocon Pharma Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Biocon Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 31 October 2014 and has been in existence for over 12 years.
Its director Kiran Mazumdar-Shaw is #102 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24232KA2014PLC077036. Its GSTIN is 29AAGCB0811M1ZN (Karnataka). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹1,040.15 Cr and a paid-up capital of ₹887.1 Cr. It is led by directors including Siddharth Mittal (Whole-Time Director) and Kiran Mazumdar Shaw.
Its last annual general meeting (AGM) was held on 08 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 20Km Electronics City Hosur Road, Bangalore – 560100, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹982.5 Cr, a growth of 11% compared to the previous year. For the same year it recorded a net profit of ₹82.3 Cr (net margin 8.4%) and EBITDA of ₹137.2 Cr (EBITDA margin 14%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years and 230% over five years.
The company has about 526 employees on its provident fund (EPFO) records.
As per MCA filings, the company has satisfied charges of ₹133 Cr on record. Court records list 4 cases involving the company, including 2 filed by the company and 2 filed against it; 1 case is pending. The company has 4 deals on record (3 acquisitions, 1 funding round), with disclosed funding of ₹5 Lakh; the latest was in May 2024. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Blue Cross Laboratories Private Limited with revenue of ₹1,021.41 Cr. The company has 15 MSME Form 1 returns on record between 2018 and 2023, listing 739 overdue payments to 148 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.
Company details
CIN U24232KA2014PLC077036
Registration Number 077036
Incorporation Date 31 October 2014
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Biocon Limited
Compliance Status Active Compliant
Key People
Siddharth Mittal Whole-Time Director Soudabi Neduvanchery Cfo Kiran Mazumdar Shaw Director Recognitions & Rankings of Biocon Pharma
Contact details
Biocon Pharma Limited's registered office is in Bangalore, Karnataka. Its website is biocon.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address20Km Electronics City Hosur Road, Bangalore – 560100, Karnataka, India – 560100
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Biocon Pharma Limited, buy the company report.
Comprehensive company report
Biocon Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Biocon Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Biocon Pharma Limited, buy the company report.
Financials of Biocon Pharma Limited
FY 2025 filings availableBiocon Pharma Limited reported revenue of ₹982.5 Cr (up 11% YoY) for FY 2025.
Revenue · FY 2025
₹982.5 Cr ▲ 11%
Net profit · FY 2025
₹82.3 Cr margin 8.4%
EBITDA · FY 2025
₹137.2 Cr margin 14%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 11%
3 years · compounded
▲ 16%
5 years · compounded
▲ 230%
EBITDA CAGR growth
1 year
▲ 122%
3 years · compounded
▼ 1%
5 years · compounded
▲ 33%
Revenue has grown at a compounded annual rate (CAGR) of 230% over five years, including 11% growth in the latest year. EBITDA rose 122% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹137.2 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹82.3 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14% | ||||
| Net Profit Margin | 8.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Biocon Pharma Limited, buy the company report.
Board of directors and KMP of Biocon Pharma Limited
Biocon Pharma Limited currently reports 3 directors and 1 key managerial person. 10 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kiran Mazumdar Shaw | Director | 31 Oct 2014 | 11 Years 11 Months | Current |
| Siddharth Mittal | Whole-Time Director | 23 Jan 2020 | 6 Years 8 Months | Current |
| Soudabi Neduvanchery | Cfo | 08 Aug 2024 | 2 Years 2 Months | Current |
| Karaikal Narayanaswamy Murali Krishnan Also directs: Biocon Biosphere Limited | Director | 13 May 2022 | 4 Years 5 Months | Current |
Peer comparison
Biocon Pharma Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Blue Cross Laboratories Private Limited | ₹1,021.41 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Win-Medicare Private Limited | ₹1,012.12 Cr (FY 2025) | 7.0% | New Delhi, Delhi, India | |||
| Umedica Laboratories Private Limited | ₹993.72 Cr (FY 2025) | 21.0% | Pardi, Gujarat, India | |||
| Franco-Indian Pharmaceuticals Private Limited | ₹988.53 Cr (FY 2024) | 0.0% | Mumbai, Maharashtra, India | |||
| Meyer Organics Private Limited | ₹984.18 Cr (FY 2025) | 12.0% | Thane, Maharashtra, India | |||
| Biocon Pharma Limitedthis company | ₹982.5 Cr (FY 2025) | ₹82.3 Cr | 8.4% | 11.0% | 526 | Bangalore, Karnataka, India |
| Orchid Pharma Limited | ₹949.4 Cr (FY 2025) | 12.0% | Chengalpattu, Tamil Nadu, India | |||
| Fresenius Kabi India Private Limited | ₹934 Cr (FY 2025) | 10.0% | Ranjangaon, Maharashtra, India | |||
| Lee Pharma Limited | ₹928.7 Cr (FY 2025) | 2.0% | Hyderabad, Telangana, India | |||
| Punjab Chemicals and Crop Protection Limited | ₹901.95 Cr (FY 2025) | -4.0% | Derabassi, Punjab, India |
To see the full peer comparison of Biocon Pharma Limited, buy the company report.
Auditor
Biocon Pharma Limited is audited by BSR & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BSR & Co. LLP | FY 2023 | 101248W/W-100022 |
Shareholding
The shareholding of Biocon Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Biocon Pharma Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹133 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Sep 2016 | 100057801 | Citi Bank N.A. | ₹133 Cr | Satisfied |
To see the full charge records of Biocon Pharma Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Biocon Pharma Limited has 4 deals on record (3 acquisitions, 1 funding round), with disclosed funding of ₹5 Lakh; the latest was in May 2024.
Total deals
4
Acquisitions
3
Funding round
1
Disclosed funding
₹5 Lakh
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2024 | Funding round | ₹5 Lakh | Investors: Biocon Limited |
| Oct 2020 | Acquisition | ₹596.94 Cr | Buyer: Biocon Limited |
| Sep 2018 | Acquisition | ₹276.06 Cr | Buyer: Biocon Limited |
| Mar 2016 | Acquisition | ₹14 Cr | Buyer: Biocon Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Biocon Pharma Limited has 4 court cases on record: 2 filed by Biocon Pharma, 2 filed against it. 1 case is pending and 3 are disposed.
Total cases
4
Filed by the company
2
Filed against the company
2
Pending
1
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| NCLT | 2 | 0 | 0 |
| District courts | 1 | 1 | 1 |
| High courts | 1 | 1 | 0 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Court case (Com.A.P.) | Filed against the company by Airis Pharma Pvt Ltd | Pending |
| High Court, KARNATAKA | Interim or miscellaneous application | Filed against the company by Airis Pharma Pvt Ltd | Disposed |
| NCLT, Hyderabad | Insolvency matter | Filed by the company against Airis Pharma Private Limited | Disposed |
| NCLT, Bengaluru | Court case (C.P.(CAA)) | Filed by the company | Disposed |
To see the full case history of Biocon Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Biocon Pharma Limited has 15 MSME Form 1 returns on record between 2018 and 2023, listing 739 overdue payments to 148 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 148)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Oaisis Alcohol India Private Limited | |||
| an individual supplier | |||
| Ultra International | |||
| an individual supplier |
To see the full MSME payment records of Biocon Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Biocon Pharma Limited has a workforce of 526 employees on its EPFO records as of Mar 29, 2024, across 1 active EPFO establishment.
Employee count
526
Active EPFO establishments
1
Employee growth
6.91%
GST
Biocon Pharma has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAGCB0811M1ZN | Karnataka | Active | 01 Jul 2017 |
| 29AAGCB0811M2ZM | Karnataka | Active | 07 Jul 2017 |
To see the full GST registrations and return filing status of Biocon Pharma Limited, buy the company report.
Recent activity
Biocon Pharma Limited has 13 board changes on record since 2014: 4 appointments and 9 cessations. The latest: Soudabi Neduvanchery was appointed as CFO on 08 Aug 2024.
AGM
Biocon Pharma Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records.
Filing
Biocon Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Appointed
Soudabi Neduvanchery was appointed as CFO.
Ceased
John Mccallum Marshall Shaw ceased to be Director.
Ceased
Karaikal Narayanaswamy Murali Krishnan ceased to be Additional Director.
Charges
A charge registered on 29 Sep 2016 via Charge ID 100057801 with Citi Bank N.A. was fully satisfied on 31 May 2022.
Appointed
Karaikal Narayanaswamy Murali Krishnan was appointed as Director.
Ceased
Anupam Jindal ceased to be CFO.
Ceased
Indranil Sen ceased to be CFO.
Ceased
Arun Suresh Chandavarkar ceased to be Ceo(Kmp).
Appointed
Siddharth Mittal was appointed as Whole-Time Director.
Ceased
Siddharth Mittal ceased to be Additional Director.
6 earlier events are in the company report.
News
Frequently asked questions
Biocon Pharma is an active public limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 31 October 2014 (12+ years old) and is registered under CIN U24232KA2014PLC077036.
Biocon Pharma has 4 current directors and KMP:
- Siddharth Mittal - Whole-Time Director
- Kiran Mazumdar Shaw - Director
- Karaikal Narayanaswamy Murali Krishnan - Director
- Soudabi Neduvanchery - Cfo
The latest financial statements of Biocon Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 08 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Biocon Pharma is 29AAGCB0811M1ZN, registered in Karnataka. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 29AAGCB0811M2ZM (Karnataka).
The CIN (Corporate Identification Number) of Biocon Pharma is U24232KA2014PLC077036. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Biocon Pharma has 4 court cases on record: 2 filed by the company and 2 filed against it. 1 is pending. Most are in the nclt.
Biocon Pharma was incorporated on 31 October 2014, making it 12+ years old. It is registered with the Registrar of Companies, Bangalore.
Biocon Pharma has 4 deals on record (3 acquisitions, 1 funding round), with disclosed funding of ₹5 Lakh; the latest was in May 2024.
The peers of Biocon Pharma by revenue are Blue Cross Laboratories Private Limited, Win-Medicare Private Limited, Umedica Laboratories Private Limited, Franco-Indian Pharmaceuticals Private Limited, Meyer Organics Private Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Soudabi Neduvanchery was appointed as CFO on 08 Aug 2024. John Mccallum Marshall Shaw ceased to be Director on 31 Jul 2022. Karaikal Narayanaswamy Murali Krishnan ceased to be Additional Director on 22 Jul 2022. Biocon Pharma has 13 board changes on record in total.
Biocon Pharma has 15 MSME Form 1 returns on record between 2018 and 2023, listing 739 overdue payments to 148 micro and small suppliers. The latest return was filed on 21 Oct 2023.
Biocon Pharma can be reached through the website biocon.com. Its registered office is in Bangalore, Karnataka, India.